11/22
07:56 am
artv
Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
11/12
02:21 pm
artv
Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.
11/12
10:31 am
artv
Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]
High
Report
Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]
11/12
08:21 am
artv
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease [Yahoo! Finance]
Medium
Report
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease [Yahoo! Finance]
11/12
07:20 am
artv
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
High
Report
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
11/12
07:00 am
artv
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
High
Report
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/3
04:05 pm
artv
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
Medium
Report
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
10/30
06:27 pm
artv
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November [Yahoo! Finance]
Low
Report
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November [Yahoo! Finance]
10/30
04:17 pm
artv
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
Medium
Report
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
10/30
12:25 pm
artv
Artiva Biotherapeutics (NASDAQ:ARTV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/19
10:32 am
artv
Artiva Biotherapeutics (ARTV) Is Up 113.9% After FDA Fast Track for AlloNK in Refractory RA – Has the Bull Case Changed? [Yahoo! Finance]
Medium
Report
Artiva Biotherapeutics (ARTV) Is Up 113.9% After FDA Fast Track for AlloNK in Refractory RA – Has the Bull Case Changed? [Yahoo! Finance]
10/17
08:35 am
artv
Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at Wedbush from $18.00 to $23.00. They now have an "outperform" rating on the stock.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at Wedbush from $18.00 to $23.00. They now have an "outperform" rating on the stock.
10/17
08:12 am
artv
Artiva Biotherapeutics (NASDAQ:ARTV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
10/16
04:33 pm
artv
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update [Yahoo! Finance]
High
Report
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update [Yahoo! Finance]
10/16
04:05 pm
artv
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
High
Report
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
10/3
03:30 pm
artv
Artiva Biotherapeutics (NASDAQ:ARTV) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Artiva Biotherapeutics (NASDAQ:ARTV) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.